Table 2.
Meta-regression analysis for the relationship of the effect of antihypertensive treatment with baseline mean age
| Outcomes | Studies, n | β (95% CI)a | P value |
|---|---|---|---|
| Coronary heart disease | 16 | −0.0036 (−0.0376 to 0.0305) | 0.8370 |
| Stroke | 19 | 0.0080 (−0.0114 to 0.0274) | 0.4194 |
| Heart failure | 13 | −0.0277 (−0.0629 to 0.0076) | 0.1237 |
| Cardiovascular death | 19 | 0.0099 (−0.0092 to 0.0289) | 0.3112 |
| MACE | 15 | 0.0026 (−0.0178 to 0.0230) | 0.8033 |
| Renal failure | 7 | 0.0919 (−0.0129 to 0.1967) | 0.0858 |
| All-cause death | 19 | 0.0044 (−0.0142 to 0.0231) | 0.6411 |
| Cognitive decline | 3 | 0.0161 (−0.0171 to 0.0493) | 0.3414 |
| Dementia | 4 | 0.0308 (−0.0214 to 0.0831) | 0.2472 |
Abbreviations: CI, confidence interval; MACE, major adverse cardiovascular events.
aThe regression coefficient is the change in the risk of different outcomes for each 1-year older baseline age.